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Abstract
Objective: Potential surrogate markers of disease activity, including response to therapy, are
particularly important in a neurological disorder such as multiple sclerosis (MS) which often has a
fluctuating course. Based upon previous studies in our laboratory, we hypothesized that
measurement of soluble HLA (sHLA) molecules class II in saliva of MS patients can serve as marker
of therapeutic response to high dose interferon beta-1a.
Methods: We measured the expression patterns of sHLA-II in saliva in 17 patients with relapsing/
remitting MS and compared the results to clinical course and brain MRI. For comparison purposes
we also assayed the saliva sHLA-II levels in 53 normal control subjects. Solid phase ELISA was used
for measurement of sHLA-I and sHLA-II concentrations at baseline and after three and six months
of treatment with high dose interferon beta-1a (IFN β-1a).
Results: The mean saliva sHLA-ll levels in MS patients was significantly higher than normal controls
(354 ± 42 unit/mL vs. 222 ± 18 unit/mL, t= 8.16, p < 0.003). Comparison of saliva sHLA-II values
before and after treatment with IFN β-1a revealed a consistent increase in mean concentration.
The increase in saliva sHLA-II values (354 ± 42 unit/mL at baseline versus 821 ± 86 unit/mL at 3
months and 776 ± 63 unit/mL at 6 months, in unit/mL, p < 0.001 for both comparisons) was
associated with a stable clinical course and a decline of the number of contrast-enhancing lesions
on brain MRI. Comparison of the volume of T2-weighted lesions and the number of black holes on
T1-weighted images did not reveal any significant changes (during pre-treatment versus post-
treatment month 6) or any correlations with saliva sHLA-II levels. Saliva sHLA-I levels were not
detectable.
Conclusion: Serial measurement of saliva sHLA-II may serve as a potential marker of therapeutic
response to IFN β-1a. Larger clinical studies involving more RRMS patients over longer periods of
time are needed to further test the significance and value of saliva sHLA-II as an accurate marker
of therapeutic response to beta-interferons.
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The Human Major Histocompatibility Antigens (HLA) are
generally cell bound, but trace amounts exist in soluble
forms which circulate in serum, plasma, and other human
body fluids [1]. These soluble HLA class-I (sHLA-I) and
class-II (sHLA-II) molecules may have immunomodula-
tory function [2-4]. Normal individuals have stable con-
centrations of sHLA-I and sHLA-II in their serum [1].
However, the serum level of sHLA-I is significantly ele-
vated in patients with various inflammatory diseases [5-8]
although this is not necessarily the case for serum sHLA-II
levels [9,10]. Preliminary evidence suggests that patients
with systemic lupus erythematosus (SLE) are at increased
risk of developing active disease in the presence of high
sHLA-I levels in the saliva, while sHLA-II level has not
been observed to be elevated in rheumatological diseases
[11]. Typically, sHLA-I exists in very low quantities in the
saliva, sweat, urine and/or tears of normal individuals,
while sHLA-II is routinely detectable in all these body flu-
ids [1].
The potential role of soluble HLA in the pathogenesis of
multiple sclerosis (MS) is not presently established. Alter-
ations in sHLA-I and sHLA-II levels in the serum and CSF
of MS patients has been reported [12-14]. A trend toward
increased production of sHLA-I in the serum and CSF was
observed in MS patients after immunomodulatory ther-
apy [15]. On the other hand, sHLA-II in the serum of
untreated MS patients was found to be significantly ele-
vated compared to values obtained from MS patients
receiving corticosteroid treatment. [12] Hypothetically,
one would expect the measurement of sHLA in CSF would
be most likely to reflect CNS disease activity. Measure-
ment of such a biological marker of disease activity could
potentially serve as a monitor of response to immu-
nomodulatory treatment in MS. However, a biological
marker of disease activity, as well as response to therapy,
must be reliable, noninvasive, and preferably of reasona-
ble cost in order to be performed in a serial fashion reflec-
tive of the natural history of the relapsing/remitting form
of (RRMS).
We have previously reported a correlation between CSF
and saliva sHLA-II levels in MS patients [16]. We have
now extended our investigation to assess the possible
response of saliva sHLA-II levels in RRMS patients at base-
line and following immunomodulatory therapy with
interferon-beta1a (Rebif) (IFN-β1a).
Methods
The study was approved by Institutional Review Board of
Louisiana State University Health Sciences Center in
Shreveport and signed informed consent was obtained
from all participants.
Population studied
Saliva specimens from 17 consecutive Caucasian patients
with RRMS, defined by the McDonald criteria [17], were
collected and analyzed. None of the patients were on
immunomodulating therapy or immunosuppressive ther-
apies for at least six months prior to entrance into the
study. Two patients had experienced two clinical relapses
during the six months prior to study entry, while the oth-
ers had only one relapse prior to study initiation. Because
there is a high degree of racial variation in the gene fre-
quencies of HLA, we limited study participation to Cauca-
sians born in the United States and residing in Louisiana.
Collection of samples
Each subject involved in the study was asked to expecto-
rate saliva into a test tube preceded by rinsing of the
mouth with sterile water as previously described [16]. In
addition, saliva specimens from 53 healthy age and sex
matched individuals were used for comparison. Collected
saliva samples were stored at -20C until subsequent assay.
Patient monitoring
After obtaining the first saliva specimen, patients were
treated with IFNβ-1a (Rebif®) 44 mcg subcutaneously
three times weekly. All patients underwent neurological
examination at baseline as well as at three and six months
and this included expanded disability status scores
(EDSS) during each visit.
MRI protocol
Brain MRI was performed using a 1.5 T machine with a
standard quadrature head coil. The imaging protocol
included sagittal T1-, axial T1-, T2-weighted, and fluid
attenuated inversion recovery (FLAIR) images. All MRI
scans were performed before and after (Gd-DTPA) infu-
sion. Axial T2-weighted and pre- and post-contrast T1-
weighted images were used for assessment of MS plaques.
Comparisons were made between all 17 MS patients who
were sub-grouped into either those with and those with-
out enhancing lesions on their MRI scans. MR imaging
was performed prior to and after six months of treatment
with IFN β-1a. Volumetric analysis of T2-weighted lesions
was performed by a neuroradiologist who delineated the
T2-weighted lesion as the area of interest; the volume was
calculated by multiplying the total area of interest by the
slice thickness. The results were expressed in cubic millili-
ters (Zivadinov 2001). The numbers of T1-weighted black
holes, pre- and post-treatment, were determined qualita-
tively by number count.
Measurement of soluble HLA
A solid phase ELISA was used to quantitate s-HLA-I and s-
HLA-II in the saliva obtained from study subjects. The
immuno-affinity purification and quantitation of s-HLA-I
and s-HLA-II has been previously described [18]. ThisPage 2 of 6
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agulants, freezing or thawing. Briefly, test specimens were
added to appropriate wells containing an anti-Class I (w6/
32) or anti-Class II (Ab 2.06) monoclonal antibody
(Mab) coated beads. The reaction proceeds 30 minutes for
sHLA-I and 2 hours for sHLA-II at 45°C. The beads are
then washed three times with distilled water. Following
this, 200 ul of peroxidase labeled anti-beta2 microglobu-
lin (L368) for sHLA-I and L.2.03 Mab for sHLA-II were
added to each bead and incubated for an additional hour
at 45°C. After additional washes, the color reaction was
started by adding O-phenylenediamine as a substrate. The
color intensity is proportional to sHLA concentration.
Absorbance was measured at 492 nm. Saliva levels of
sHLA-II were measured at baseline as well as at 3 and 6
months after treatment with IFN β-1a. Saliva sHLA-II con-
centrations pre and post-treatment were compared to the
neurological status of the patient as well as to the MRI
brain scan findings.
Statistical analysis
Using the Friedman non-parametric method [19], we
compared the mean values for saliva sHLA-II in study sub-
jects and normal controls. Paired comparison of changes
from baseline to post-treatment was performed with use
of Wilcoxon signed rank test. Correlations were deter-
mined with Spearman's non-parametric correlation
method.
Results
Demographics of study subjects are presented in Table 1.
Soluble HLA saliva levels. Scatter plots of distribution of
saliva levels of sHLA-II of MS patients pre- and post-treat-
ment with IFN-β1a is presented in two scatter plots (Fig-
ures 1A and 1B). All study subjects with RRMS had
measurable amounts of sHLA-II in their saliva and in all
subjects increases in saliva sHLA-II levels following treat-
ment with IFN-β1a (at month 6 post-treatment) were
detected. The mean value of sHLA-II was 354 ± 42 (unit/
mL) baseline, 821 ± 86 (unit/mL) at month 3, and 776 ±
63 (unit/mL) at month 6 (p < 0.001) for both. Correlation
analysis of pre-versus post-treatment saliva sHLA-II levels
at month 3 was significant r =.51, p=.035; however, was
not significant for measurement at month 6 r =.063, p =
.81. Furthermore, we did not observe any discernible rela-
tionship between pre- and post-treatment saliva sHLA-II
levels and subjects' clinical status. Additionally, we did
not observe any specific relationship between the baseline
saliva sHLA-II levels and follow up values. All normal con-
trols had detectable amounts of sHLA-II in the saliva with
a mean value of 222 ± 18 unit/mL.
Neurological status
During the six months of treatment, only one patient had
a documented clinical relapse with optic neuritis.
Correlation with MRI brain scan results
Of particular interest, the increase in sHLA-II values was
associated with a decline on brain MRI activity as demon-
strated by post-contrast T1-weighted axial brain images.
Initially, six patients had contrast enhancing lesions on
axial post-contrast T1-weighted brain MR images. Com-
parison of brain MRI at months 0 and 6 did not show any
new contrast-enhancing lesions. Comparison of the mean
volumes of T2-weighted lesions as well as the average
count of T1-weighted black holes, pre-versus post-treat-
ment, did not show any significant differences (p = 0.381
and p = 0.89 respectively). Additionally, we did not
observe a correlation between the volume of T2-weighted
lesions or the number of T1-weighted black holes with
saliva sHLA-II levels.
Correlation of sHLA levels with disability status
At six months, all subjects exhibited a one-grade or greater
decrease in their EDSS scores (p < 0.001) which occurred
in association with elevated levels of saliva sHLA-II levels
at month 6.
Discussion
There are a number of important reasons to have a reliable
surrogate marker for disease activity in RRMS. As the name
implies, there can be a significant day-to-day fluctuation
in this form of MS. Furthermore, response to interferon
beta, the most common form of immunomodulating
therapy, can vary with only 30 to 40% of patients reported
to have a good response [20,21]. This may, in part, be
related to the formation of anti-interferon beta neutraliz-
ing antibodies [22]. In an effort to address this issue, in
terms of a marker of response, levels of interferon inhibi-
tory activity (IIa) were measured in a recent study and
reported to be an indicator of therapeutic efficacy [23].
Efforts have also been made to determine clinical and
demographic indicators of disease activity in an effort to
predict the clinical course over time [24]. Colucci et al.
[25] measured CSF levels of protein 14-3-3 in patients
with demyelinating disorder and reported that, in some
patients, protein 14-3-3 may serve as a marker of disease
severity and risk to develop disability. The monitoring of
Table 1: Demographic and MRI features of the MS subjects
Number of MS patients 17 (F/M = 11/6)
Age (Mean ± SD) 29 ± 3 years
MS duration prior to diagnosis 9 ± 2 months
Number of T1-weighted post-contrast enhancing 
lesions
At least one at month 0 (N = 6)
At least one at month 6 (N = 0)
Number of relapses during the six months prior to 
study entry
Two relapses (N = 2)
One relapse (N = 15)Page 3 of 6
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may have additional value as particularly effective immu-
nomodulatory activity, such as that observed with natali-
zumab, may have a potential downside [26] that is better
to detect sooner rather than later.
The mechanisms for secretion or excretion of sHLA class I
and II in various human body fluids remain unknown. It
has been suggested that liver cells and activated immuno-
competent cells actively secrete sHLA-I into the serum
[27]. sHLA-II may also be shed or secreted into serum and
other body fluids by certain immune processes. However,
the potential immunoregulatory function of these mole-
cules can not be elucidated as currently there are no spe-
cific monoclonal antibodies for class II allotypes
available. Furthermore, it would be unlikely that the same
mechanism(s) would account for sHLA release in various
body fluids as immune reactive cells are not typically
present in body fluids, except in pathological states.
We demonstrated, in studies of sHLA-I in serum, sweat,
and saliva, that saliva contains polymorphic structures
identical to those of serum sHLA-I, but the concentration
of sHLA-I was very small [1]. It is possible that HLA
appears in other body fluids en route to sites of catabo-
lism or excretion as a consequence of a specific physiolog-
ical event. Serum sHLA-II has been reported to be low or
undetectable in most normal individuals tested [9], while
it is commonly present in the saliva, sweat and tears of
normals [1,11]. Soluble HLA-II has also been reported in
the synovial fluid of patients with active rheumatoid
arthritis, but not in the serum [10,28], which in turn sup-
ports the concept of selective distribution of sHLA-II
within body fluids.
Based on the literature to date, sHLA levels appear to cor-
relate with RRMS disease activity [12-16]. However, our
knowledge about the dynamics of soluble HLA in MS
patients, as an indicator of both disease activity and
response to immunomodulatory therapy, is marginal and
further studies are needed. Recently, Fainardi et al [15]
described a trend towards increased production of sHLA-I
in the serum of patients with MS following the treatment
with IFN β-1b. However, we have observed a decrease in
serum sHLA-II levels after therapy with IFN β-1a in MS
patients [29]. A recent report by Mitsdoerffer et al [30]
suggests that although both IFN-β and IFN-γ significantly
increase sHLA-G1 and sHLA-G5 (non-classical HLA-class-
I) expression by monocytes in vitro, IFN-β treatment is
associated with higher upregulation of HLA-G compared
to classic HLA-I molecules than stimulation with IFN-γ.
Since monocyte-derived HLA-G inhibits autologous CD4
T cell activation, its upregulation by IFN-β was considered
as one of the mechanisms of action of IFN-β.
In the present study, longitudinal measurement of saliva
sHLA-II levels over a six month period demonstrated ele-
vation of saliva sHLA-II levels in association with IFN β-1a
therapy in MS (p < 0.0001). Collectively taken, our results
indicate that treatment of MS patients with IFN β-1a pro-
(A) Scattergram of baseline and three-month levels of sHLA-IIFigure 1
(A) Scattergram of baseline and three-month levels of sHLA-II. The correlation is significant, ρ = .51, p = 0.035. (B) Scattergram 
of baseline and six-month levels of sHLA-II. The correlation is not significant, ρ = .063, p = 0.81.Page 4 of 6
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sHLA-II after six month of therapy. Such a pronounced
response may indicate that IFN β-1a up-regulates the
expression of HLA class II genes/molecules. The elevation
of saliva sHLA-II in our patients, in association with clin-
ical and MRI stability, may also be indicative of a favora-
ble therapeutic response to IFN β-1a. Further studies
involving larger cohorts of MS patients and over longer
follow up periods are necessary to assess the potential of
sHLA-II as a marker of disease activity and response to
therapy in MS.
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